文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

苄青霉素对比氟氯西林或氯唑西林治疗青霉素敏感金黄色葡萄球菌菌血症(SNAP):一项国际、多中心、开放标签、非劣效性随机对照试验

Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.
PubMed 文献 · Lancet · 2026-06-17
一句话结论在成人青霉素敏感金黄色葡萄球菌菌血症中,苄青霉素虽未达到预设非劣效界值,但死亡概率非劣效且急性肾损伤风险更低,作者认为应优先选用苄青霉素而非氟氯西林或氯唑西林。

SNAP平台PSSA子研究纳入67家医院、493例成人青霉素敏感金黄色葡萄球菌菌血症患者,1:1随机接受苄青霉素或氟氯西林/氯唑西林。苄青霉素组90天死亡21/152(14%),氟氯西林/氯唑西林组26/121(22%),校正OR 0.67(95%CrI 0.35-1.28),苄青霉素非劣效后验概率96.1%、优效概率88.9%,未达预设非劣效界值(校正OR<1.20)。急性肾损伤苄青霉素组17/153(11%) vs 氟氯西林/氯唑西林组27/124(22%),校正OR 0.50(95%CrI 0.26-0.94),非劣效后验概率99.8%、优效概率98.4%。数据安全监察委员会因氟氯西林/氯唑西林组急性肾损伤增加而建议提前终止招募。作者认为,尽管未达预设非劣效标准,苄青霉素死亡非劣效概率高且急性肾损伤风险更低,应优先选用苄青霉素。

要点

  • 成人PSSA菌血症:苄青霉素组90天死亡14%(21/152) vs 氟氯西林/氯唑西林组22%(26/121),校正OR 0.67(95%CrI 0.35-1.28),非劣效后验概率96.1%,未达预设非劣效界值(校正OR<1.20)。
  • 急性肾损伤:苄青霉素组11%(17/153) vs 氟氯西林/氯唑西林组22%(27/124),校正OR 0.50(95%CrI 0.26-0.94),优效后验概率98.4%。
  • 数据安全监察委员会因氟氯西林/氯唑西林组急性肾损伤增加,在预设终止界值前建议停止招募,PSSA子研究于2024年8月7日关闭招募。
  • 严重不良反应:苄青霉素组6/156(4%)报告7例次,氟氯西林/氯唑西林组9/125(7%)报告10例次。
  • 作者结论:尽管未达预设非劣效标准,苄青霉素死亡非劣效概率高且急性肾损伤风险更低,成人PSSA菌血症应优先选用苄青霉素而非氟氯西林或氯唑西林。

适用人群与场景

  • 成人(年龄≥18岁)青霉素敏感金黄色葡萄球菌菌血症住院患者,来自澳大利亚、新西兰、加拿大、以色列、荷兰、英国、新加坡和南非的67家医院。
  • SNAP试验PSSA子研究纳入所有年龄患者,本报告仅成人结果;排除人群原文未报告。

诊断标准与关键阈值

  • 青霉素敏感金黄色葡萄球菌(PSSA)菌血症。
  • 非劣效界值:苄青霉素校正比值比(OR)<1.20 定义为非劣效。

处置流程与药物剂量

  • 苄青霉素推荐标准剂量:1.8 g 静脉注射 每4小时一次,或 2.4 g 每6小时一次。
  • 氟氯西林推荐标准剂量:2.0 g 静脉注射 每6小时一次。
  • 氯唑西林推荐标准剂量:2.0 g 静脉注射 每4小时一次;仅在无氟氯西林时使用(即加拿大、以色列、新加坡和南非)。
  • 随机分配1:1至苄青霉素组或氟氯西林/氯唑西林组;试验人员、照护人员和参与者均知晓分组。

红旗征与不能漏的情况

  • 氟氯西林或氯唑西林组急性肾损伤发生率更高(22% vs 苄青霉素组11%),数据安全监察委员会因此建议提前终止招募。

研究设计与关键结果

  • 国际、多中心、开放标签、非劣效性随机对照试验,嵌套于SNAP试验PSSA子研究;2022年2月18日至2024年6月21日,493例成人PSSA菌血症中125例随机至氟氯西林/氯唑西林组、156例至苄青霉素组;中位年龄67岁(IQR 56-77),女性87例(31%),男性194例(69%)。
  • 主要终点90天全因死亡:苄青霉素组21/152(14%) vs 氟氯西林/氯唑西林组26/121(22%),校正OR 0.67(95%CrI 0.35-1.28),苄青霉素非劣效后验概率96.1%、优效后验概率88.9%。
  • 急性肾损伤:苄青霉素组17/153(11%) vs 氟氯西林/氯唑西林组27/124(22%),校正OR 0.50(95%CrI 0.26-0.94),非劣效后验概率99.8%、优效后验概率98.4%。
  • 严重不良反应:苄青霉素组6/156(4%)报告7例次,氟氯西林/氯唑西林组9/125(7%)报告10例次。
  • 因氟氯西林/氯唑西林组急性肾损伤增加,数据安全监察委员会在第四次期中分析后建议在预设终止界值前停止招募,PSSA子研究于2024年8月7日关闭招募。

证据类型、等级与局限

  • 证据类型:国际、多中心、开放标签、非劣效性随机对照试验(SNAP试验PSSA子研究)。
  • 主要终点采用分层贝叶斯逻辑回归模型分析,非劣效定义为校正OR<1.20;苄青霉素非劣效后验概率96.1%,未达到预设非劣效界值。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尽管预设非劣效标准未达到,苄青霉素死亡非劣效概率高且急性肾损伤风险更低,成人PSSA菌血症应优先选用苄青霉素而非氟氯西林或氯唑西林。
  • 对于成人PSSA菌血症,使用氟氯西林或氯唑西林时需注意急性肾损伤风险(氟氯西林/氯唑西林组22% vs 苄青霉素组11%)。
  • 苄青霉素推荐标准剂量为1.8 g 静脉注射 每4小时一次或2.4 g 每6小时一次;氟氯西林2.0 g 静脉注射 每6小时一次;氯唑西林2.0 g 静脉注射 每4小时一次(仅在无氟氯西林时使用)。

指南或共识出处

  • SNAP试验(金黄色葡萄球菌网络适应性平台试验),注册号ClinicalTrials.gov NCT05137119。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Previously considered rare, penicillin-susceptible Staphylococcus aureus (PSSA) bacteraemia has re-emerged worldwide. Although benzylpenicillin might offer advantages in terms of pharmacokinetic and adverse effect profiles, anti-staphylococcal penicillins are recommended for serious infections because of concern over undetected penicillin resistance. We aimed to compare benzylpenicillin with anti-staphylococcal penicillins (cloxacillin or flucloxacillin) for the treatment of PSSA bacteraemia in adults.

METHODS: This investigator-initiated, international, multicentre, open-label, non-inferiority, randomised controlled trial was conducted within the PSSA silo of the backbone domain of the ongoing S aureus Network Adaptive Platform (SNAP) trial. We enrolled patients of all ages who were admitted with S aureus bacteraemia at 67 hospitals across Australia, New Zealand, Canada, Israel, the Netherlands, the UK, Singapore, and South Africa. Herein, we report results for adult patients (aged ≥18 years). Participants were randomly allocated 1:1 to receive either benzylpenicillin, or flucloxacillin or cloxacillin. Trial staff, staff caring for participants, and participants were aware of the treatment allocated and received. Cloxacillin was used only where flucloxacillin was not available (ie, Canada, Israel, Singapore, and South Africa). Recommended standard dosing for benzylpenicillin was 1·8 g intravenously once every 4 h or 2·4 g once every 6 h; for flucloxacillin 2·0 g intravenously once every 6 h; and for cloxacillin 2·0 g intravenously once every 4 h. The primary outcome was all-cause mortality 90 days after platform entry, assessed in the intention-to-treat population, including all patients with available data. The primary outcome was analysed by use of a hierarchical Bayesian logistic regression model, with non-inferiority of benzylpenicillin defined as an adjusted odds ratio (OR) of less than 1·20. Analyses occurred after every 500 participants reached 90-day follow-up. The SNAP trial is registered with ClinicalTrials.gov (NCT05137119) and is ongoing.

FINDINGS: Following the fourth interim analysis, the data and safety monitoring committee recommended ceasing recruitment before prespecified stopping thresholds were reached because of increased acute kidney injury (AKI) in participants receiving flucloxacillin or cloxacillin, and the PSSA silo was closed for recruitment on Aug 7, 2024. Between Feb 18, 2022, and June 21, 2024, of 493 adults with PSSA bacteraemia, 125 were randomly assigned to the flucloxacillin or cloxacillin group and 156 to the benzylpenicillin group. The median age was 67 years (IQR 56-77), 87 (31%) were female, and 194 (69%) were male. 21 (14%) of 152 in the benzylpenicillin group and 26 (22%) of 121 in the flucloxacillin or cloxacillin group met the primary outcome of death at 90 days (adjusted OR 0·67, 95% credible interval [CrI] 0·35-1·28), with a posterior probability of benzylpenicillin non-inferiority of 96·1% and of benzylpenicillin superiority of 88·9%. AKI occurred in 17 (11%) of 153 patients in the benzylpenicillin group and 27 (22%) of 124 patients in the flucloxacillin or cloxacillin group (adjusted OR 0·50, 95% CrI 0·26-0·94), corresponding to a posterior probability of non-inferiority of benzylpenicillin of 99·8% and superiority of benzylpenicillin of 98·4%. Seven total serious adverse reactions were reported from six (4%) of 156 participants in the benzylpenicillin group and ten were reported from nine (7%) of 125 participants in the flucloxacillin or cloxacillin group.

INTERPRETATION: Although the prespecified non-inferiority criterion for benzylpenicillin was not met, the probability of benzylpenicillin being non-inferior for mortality, along with a reduction in risk of AKI, indicates that benzylpenicillin should be preferred over flucloxacillin or cloxacillin for treatment of PSSA bacteraemia in adults.

FUNDING: National Health and Medical Research Council, Medical Research Future Fund, Canadian Institutes of Health Research, Accelerating Clinical Trials Consortium, UMC Utrecht, ZonMW Good Use of Medicines programme, Health Research Council of New Zealand, Starship Foundation, National Healthcare Group Fund, National Medical Research Council, National Institute for Health and Care Research, Medical Research Council, and Paterson Family Foundation.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial. Lancet. 2026. PMID: 42309115. doi:10.1016/S0140-6736(26)00761-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。